<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'>See below for a survey for those who may have </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'>metastatic castrate-sensitive prostate cancer (mCSPC).<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'>Glen</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#1F497D'><o:p> </o:p></span></p><div style='border:none;border-top:solid #B5C4DF 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'>From:</span></b><span lang=EN-US style='font-size:10.0pt;font-family:"Tahoma","sans-serif"'> Jackie Manthorne [mailto:jmanthorne@survivornet.ca] <br><b>Sent:</b> October 10, 2019 2:54 PM<br><b>To:</b> Jackie Manthorne<br><b>Subject:</b> Opportunity to provide feedback on a new treatment for patient group submission to pCODR<o:p></o:p></span></p></div><p class=MsoNormal><o:p> </o:p></p><div><p class=MsoNormal>Dear friends,<o:p></o:p></p><div><p class=MsoNormal><o:p> </o:p></p></div><div><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'>The Canadian Cancer Survivor Network invites you and your colleagues to complete a survey to provide us with insights and perspectives about living with and managing prostate cancer in order to complete a patient evidence submission for apalutamide, a new medication for metastatic castrate-sensitive prostate cancer (mCSPC).</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'> </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'>The pan-Canadian Oncology Drug Review invites patient groups like CCSN to prepare and send in submissions so that patients and caregivers like you can be heard. Please join us and have your voice included in this important submission process.</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'> <br>If you do not have metastatic castrate-sensitive prostate cancer (mCSPC), but believe that you would benefit from this treatment, please complete the survey.</span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#333333'><br></span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>The survey will remain open until October 23, 2019. <o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>To access the survey, please go to </span><span style='font-family:"Arial","sans-serif"'><a href="https://www.surveymonkey.com/r/FHB52HN">https://www.surveymonkey.com/r/FHB52HN</a> </span><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Thank you for your participation. <o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Best,<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'>Jackie<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal>-- <o:p></o:p></p><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><p class=MsoNormal>Jackie Manthorne<o:p></o:p></p></div><div><p class=MsoNormal>President and CEO<o:p></o:p></p></div><div><p class=MsoNormal>Présidente et chef de la direction<o:p></o:p></p></div><div><p class=MsoNormal>Canadian Cancer Survivor Network<o:p></o:p></p></div><div><p class=MsoNormal>Réseau canadien des survivants du cancer<o:p></o:p></p></div><div><p class=MsoNormal>1750 croissant Courtwood Crescent, Suite 210<o:p></o:p></p></div><div><p class=MsoNormal>Ottawa, ON K2C 2B5<o:p></o:p></p></div><div><p class=MsoNormal>Telephone / Téléphone : 613-898-1871<o:p></o:p></p></div><div><p class=MsoNormal>E-mail / Courriel : <a href="mailto:jmanthorne@survivornet.ca" target="_blank">jmanthorne@survivornet.ca</a><o:p></o:p></p></div><div><p class=MsoNormal>Web site / site web: <a href="http://www.survivornet.ca" target="_blank">www.survivornet.ca</a><o:p></o:p></p></div><div><p class=MsoNormal>Blog: <a href="http://jackiemanthornescancerblog.blogspot.com/" target="_blank">http://jackiemanthornescancerblog.blogspot.com/</a><o:p></o:p></p></div><div><p class=MsoNormal>Twitter: @<a href="http://survivornet.ca" target="_blank">survivornetca</a><o:p></o:p></p></div><div><p class=MsoNormal><o:p> </o:p></p></div><div><div><div><div><div><p class=MsoNormal><span style='font-size:9.5pt'>-----------------------------------------------------------<o:p></o:p></span></p></div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><div><p class=MsoNormal><span style='font-family:"Arial","sans-serif";color:#222222'><img border=0 width=420 height=140 id="_x0000_i1025" src="cid:image001.png@01D58016.428ED370" alt="SIG_ Oct. 10 Webinar2.png"><o:p></o:p></span></p></div><p class=MsoNormal style='background-image:initial;background-position:initial;background-repeat:initial'><b><span style='font-size:9.5pt;font-family:"Arial","sans-serif";color:#222222'>Register now for our next free webinar!</span></b><span style='font-size:11.0pt;font-family:"Calibri","sans-serif";color:#222222'><o:p></o:p></span></p><p class=MsoNormal><b><u><span style='font-size:9.5pt;font-family:"Arial","sans-serif";color:#0000EE'><a href="https://attendee.gotowebinar.com/register/6023479141675278091" target="_blank">What to Know About Clots and Cancer</a><br></span></u></b><b><span style='font-size:9.5pt;font-family:"Arial","sans-serif";color:#222222'>Thursday, October 10 | 1-2 p.m. ET</span></b><span style='font-family:"Arial","sans-serif";color:#222222'><o:p></o:p></span></p></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></body></html>